Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CTI-1601 in Adult Subjects With Friedreich's Ataxia
NCT05579691Phase 2Completed
- Sponsor
- Larimar Therapeutics
- Start
- Sep 2022
- Primary completion
- Dec 2023
- Modality
- Replacement Enzymes, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Friedreich ataxia (FA) comparing Nomlabofusp (CTI-1601) with Placebo (2 arms). Primary endpoint: Treatment Emergent Adverse Events. Started Sep 2022; status: completed.
02
Drugs
nomlabofusp
03
Conditions
Friedreich ataxia (FA)
Beyond the preview
Go deeper on NCT05579691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05579691.